Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Vaccines & Immunizations


Section Navigation
			
			CDC Home








Use of COVID-19 Vaccines in the United StatesInterim Clinical Considerations						Print
																Related Pages
										Healthcare providers who administer the Moderna COVID-19 Vaccine (2023-2024 Formula) to individuals ages 6 months through 11 years should ensure the correct volume of the vaccine (0.25 mL) is withdrawn from the vial and administered to the recipient. Discard vial and excess volume after extracting a single dose.
For additional information, see FDA Announcement and Moderna COVID-19 Vaccine (2023-2024 Formula) Healthcare Provider Fact Sheet (fda.gov)
Summary of recent changes (last updated February 12, 2024):Post-vaccination reaction information updated in sections on pre-vaccination counseling and safety considerations for mRNA and Novavax vaccines to better align with EUA fact sheets for health care providers and package inserts.
Information on the availability of the V-safe safety monitoring system for updated (2023–2024 Formula) Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines added to the section on reporting of vaccine adverse events.

Reference MaterialsCOVID-19 Vaccine Product Information (Updated 11/6/2023)
FAQs for the Interim Clinical Considerations (Updated 11/3/2023)
COVID-19 Vaccination Recommendations Infographic (Updated 10/13/2023)
COVID-19 Vaccination Recommendations Infographic (Immunocompromised) (Updated 10/13/2023)Get Email UpdatesReceive email updates about this page.
What’s this?Get Email UpdatesCOVID-19 Vaccines, Recommendations, and SchedulesOverview of COVID-19 vaccination
Guidance for people who are **not** immunocompromised
Guidance for people who **are** immunocompromisedImplementationTiming, spacing, age transitions, and simultaneous administration
Interchangeability of COVID-19 vaccines
Vaccination and SARS-CoV-2 laboratory testing
Patient counselingSafetyContraindications and precautions
Reporting of vaccine adverse events
Safety considerations for mRNA COVID-19 vaccines: Moderna and Pfizer-BioNTech
Safety considerations for Novavax COVID-19 Vaccine
COVID-19 vaccination and myocarditis and pericarditisSpecial Situations and PopulationsCOVID-19 vaccination and SARS-CoV-2 infection
COVID-19 vaccination and MIS-C and MIS-A
Pregnancy, lactation, and fertilityAppendicesPeople who received COVID-19 vaccine outside the United States (Appendix A)
Vaccine administration errors and deviations (Appendix B)
							
					
							Last Reviewed:  October 6, 2023						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeCOVID-19 Vaccination
Product Info by U.S. Vaccineplus icon
EUA
EUI
Interim Clinical Considerationsplus icon
Use of COVID-19 Vaccines in the U.S.
Use of COVID-19 Vaccines in the U.S.: Appendices
FAQs for the Interim Clinical Considerations
Myocarditis and Pericarditis Considerations
Clinical Care
Provider Requirements and Support
Vaccine Recipient Educationplus icon
Talking with Patients about COVID-19 Vaccination
How to Tailor COVID-19 Information to Your Audience
How to Address COVID-19 Vaccine Misinformation
Health Departments
Planning & Partnerships
6 Things to Know
Equity in Childhood COVID-19 Vaccination
COVID-19 Vaccine Data Systemsplus icon
Overviewplus icon
Vaccine IT Overview
Data Reporting Requirements
Vaccine Administration Management System (VAMS)plus icon
Getting Started in VAMS
General Public User
Resources for Jurisdictions, Clinics, and Organizations
VAMS Program Information
Vaccinate with Confidenceplus icon
What Is Vaccine Confidence?
Vaccine Confidence Strategies
Rapid Community Assessment Guide
COVID-19 Vaccine Confidence Data
12 COVID-19 Vaccination Strategies for Your Community
How to Engage the Arts to Build COVID-19 Vaccine Confidence
Strategies for Reaching People with Limited Access to COVID-19 Vaccines


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue